TW201241182A - Method of production of sialylated antibodies - Google Patents

Method of production of sialylated antibodies Download PDF

Info

Publication number
TW201241182A
TW201241182A TW101106076A TW101106076A TW201241182A TW 201241182 A TW201241182 A TW 201241182A TW 101106076 A TW101106076 A TW 101106076A TW 101106076 A TW101106076 A TW 101106076A TW 201241182 A TW201241182 A TW 201241182A
Authority
TW
Taiwan
Prior art keywords
ser
val
thr
pro
lys
Prior art date
Application number
TW101106076A
Other languages
English (en)
Chinese (zh)
Inventor
Francis Blanche
Beatrice Cameron
Bruno Genet
Fabienne Soubrier
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of TW201241182A publication Critical patent/TW201241182A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW101106076A 2011-02-24 2012-02-23 Method of production of sialylated antibodies TW201241182A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11305200 2011-02-24
EP11306090 2011-09-01

Publications (1)

Publication Number Publication Date
TW201241182A true TW201241182A (en) 2012-10-16

Family

ID=45774189

Family Applications (1)

Application Number Title Priority Date Filing Date
TW101106076A TW201241182A (en) 2011-02-24 2012-02-23 Method of production of sialylated antibodies

Country Status (6)

Country Link
US (1) US20140046032A1 (enExample)
EP (1) EP2678357A1 (enExample)
JP (1) JP2014508759A (enExample)
AR (1) AR085302A1 (enExample)
TW (1) TW201241182A (enExample)
WO (1) WO2012113863A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
EP2877589B1 (en) 2012-07-26 2024-03-06 Momenta Pharmaceuticals, Inc. Glycoproteins with anti-inflammatory properties
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
RU2711935C2 (ru) 2013-03-11 2020-01-23 Джензим Корпорейшн Сайт-специфическая конъюгация антитело-лекарственное средство посредством гликоинженерии
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
EP2855533A4 (en) 2013-03-15 2015-11-25 Momenta Pharmaceuticals Inc METHODS RELATING TO CTLA4-FC FUSION PROTEINS
EP2991666B1 (en) 2013-05-02 2020-03-25 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
US10464996B2 (en) 2013-05-13 2019-11-05 Momenta Pharmaceuticals, Inc. Methods for the treatment of neurodegeneration
JP6594860B2 (ja) * 2013-05-29 2019-10-23 エフ．ホフマン−ラ ロシュ アーゲー シアル酸付加の定量的調節
EP3017057B1 (en) 2013-07-05 2019-10-02 F.Hoffmann-La Roche Ag Process for the mono- and bi-sialylation of glycoproteins employing n-terminally truncated beta-galactoside alpha-2,6-sialyltransferase mutants
EP2824176A1 (en) 2013-07-11 2015-01-14 Siamed'xpress Methods for producing sialylated therapeutic proteins
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
WO2015057622A1 (en) * 2013-10-16 2015-04-23 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
PL3129067T3 (pl) 2014-03-19 2023-05-08 Genzyme Corporation Specyficzne dla miejsca glikomodyfikowanie ugrupowań celujących
AU2015293949B2 (en) 2014-07-21 2019-07-25 Teknologian Tutkimuskeskus Vtt Oy Production of glycoproteins with mammalian-like N-glycans in filamentous fungi
EP3037527A1 (en) * 2014-12-22 2016-06-29 F. Hoffmann-La Roche AG Sialyltransferase without CMP-dependent sialidase activity
CN107429237B (zh) 2014-12-22 2021-09-28 豪夫迈·罗氏有限公司 Cmp依赖性的唾液酸酶活性
EP3544612A4 (en) 2016-11-23 2020-05-13 Acetylon Pharmaceuticals, Inc. PHARMACEUTICAL COMBINATIONS COMPRISING A HISTONE DEACETYLASE INHIBITOR AND A CD38 INHIBITOR AND METHODS OF USING THE SAME
EP3354278A1 (en) * 2017-01-31 2018-08-01 Sanofi Neuronal cell protective effect of antibodies specific for the protofibrillar form of the beta-amyloid peptide
FR3080376B1 (fr) * 2018-04-20 2022-12-09 Lab Francais Du Fractionnement Autoanticorps hautement sialyles et leurs utilisations
MA55529A (fr) 2019-04-03 2022-02-09 Genzyme Corp Polypeptides de liaison anti-alpha bêta tcr à fragmentation réduite
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
TW202325853A (zh) * 2021-11-09 2023-07-01 美商安進公司 治療性蛋白之生產
WO2025101901A1 (en) * 2023-11-10 2025-05-15 The Board Of Trustees Of The Leland Stanford Junior University Use of sialylated ivig or igg fc region-containing protein for preventing or treating respiratory virus diseases

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5792632A (en) 1992-05-05 1998-08-11 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US5474896A (en) 1992-05-05 1995-12-12 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5830729A (en) 1996-04-18 1998-11-03 Institut Pasteur I Sce I-induced gene replacement and gene conversion in embryonic stem cells
US20020045207A1 (en) * 1997-10-31 2002-04-18 Lynne A. Krummen Glycoprotein production process
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP2082749A3 (en) 2000-07-07 2010-06-30 Bioarctic Neuroscience AB Prevention and treatment of Alzheimer's disease
EP1427828B1 (en) 2001-09-14 2010-04-28 Cellectis Random integration of a polynucleotide after in vivo linearization
AU2004208031B2 (en) 2003-01-28 2009-10-08 Cellectis Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof.
WO2007005786A2 (en) * 2005-06-30 2007-01-11 Centocor, Inc. Methods and compositions with enhanced therapeutic activity
ATE536373T1 (de) 2005-10-21 2011-12-15 Genzyme Corp Therapiemittel auf antikörperbasis mit erhöhter adcc-aktivität
US20080206246A1 (en) 2006-04-05 2008-08-28 Ravetch Jeffrey V Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
WO2008057634A2 (en) 2006-10-26 2008-05-15 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
MX2008007477A (es) 2005-12-12 2008-09-03 Ac Immune Sa Anticuerpos monoclonales especificos 1-42 beta con propiedades terapeuticas.
EP2815768A3 (en) 2006-04-05 2015-01-14 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
JP2010512306A (ja) * 2006-10-27 2010-04-22 ザ ロックフェラー ユニバーシティー 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法
AR063975A1 (es) * 2006-11-28 2009-03-04 Centelion Fusiones fc con receptor para fgf soluble modificadas con actividad biologica mejorada
PE20090993A1 (es) 2007-08-29 2009-07-08 Sanofi Aventis Anticuerpos anti-cxcr5 humanizados y derivados de los mismos
EP2650308A3 (en) 2007-10-05 2014-11-12 Genentech, Inc. Use of anti-amyloid beta antibody in ocular diseases
JP2011500059A (ja) 2007-10-15 2011-01-06 セントコア・オーソ・バイオテツク・インコーポレーテツド ヒト抗アミロイド抗体、組成物、方法及び使用
WO2009054537A1 (ja) 2007-10-25 2009-04-30 Kagoshima University アミロイドβペプチドのミミック分子を用いたペプチドワクチン
AU2008317354B2 (en) 2007-10-25 2014-04-10 Ospedale San Raffaele S.R.L. Methods and compositions for targeted integration
CN104098695B (zh) 2007-10-29 2018-09-07 道健康生活医药株式会社 抗体及其应用
EP2207568B1 (en) 2007-11-16 2017-05-31 The Rockefeller University Antibodies specific for the protofibril form of beta-amyloid protein
EP2222705B1 (en) 2007-12-11 2014-10-22 Glaxo Group Limited Antigen binding proteins
EP2233502A1 (en) 2009-03-27 2010-09-29 Deutsches Rheuma-Forschungszentrum Berlin Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them
FR2945538B1 (fr) * 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
US10087236B2 (en) * 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering

Also Published As

Publication number Publication date
WO2012113863A1 (en) 2012-08-30
EP2678357A1 (en) 2014-01-01
AR085302A1 (es) 2013-09-18
US20140046032A1 (en) 2014-02-13
JP2014508759A (ja) 2014-04-10

Similar Documents

Publication Publication Date Title
US20140046032A1 (en) Method of production of sialylated antibodies
AU2018266711B2 (en) Anti-CD3-binding domains and antibodies comprising them, and methods for their generation and use
JP7765397B2 (ja) 新規抗ｌｉｌｒｂ４抗体および派生産物
CA2946503C (en) Modified antigen binding polypeptide constructs and uses thereof
DK1896071T3 (en) Methods and compositions with increased therapeutic activity
KR20100074220A (ko) Ｃｄｒ의 아미노산 치환에 의해 항체의 등전점을 개변하는 방법
CA2963760A1 (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
TWI780097B (zh) 於活體外進行抗體之糖基化工程
WO2010074266A1 (ja) 抗cd4抗体
KR102168562B1 (ko) Cd20 및 cd95에 결합하는 재조합 이중특이성 항체
TWI781973B (zh) 用於以活體外進行抗體糖基化工程之方法
TW200808830A (en) Mutant polypeptide having effector function
MX2013015061A (es) Anticuerpo anti-cxcr4 con funciones efectoras y su uso para el tratamiento del cancer.
JP2018502550A (ja) 修飾された抗原結合ポリペプチド構築物及びその使用
JP2024112905A (ja) 抗体依存性細胞介在性細胞傷害の調節方法
TW201441258A (zh) 用於ｈｉｖ預防及治療的醣修飾抗ｃｄ４抗體
US20250101104A1 (en) Bispecific molecule with tunable affinity to a targeted antigen
US20250277041A1 (en) Anti-fgfr2 adcc enhanced antibody and use thereof
CN118475614A (zh) 具有增强的效应子功能的生物合成双互补位或双特异性结合分子
CN118414356A (zh) 具有增强的效应子功能的生物合成单价结合分子
US20250263481A1 (en) Monoclonal Antibodies Against CLDN18.2 and FC-Engineered Versions Thereof
EP4733319A1 (en) Therapeutic molecules
KR20250094703A (ko) 향상된 효과기 기능을 갖는 당조작된 Fc 변이체 폴리펩타이드
JP2026506046A (ja) グリコシル化ポリペプチド
HK40123043A (zh) 用於体外糖工程化抗体的方法